Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib

被引：1
|
作者：
Zeitler, Kristen [1 ]
Jariwala, Ripal [2 ]
Alrabaa, Sally [3 ]
Sriaroon, Chakrapol [4 ]
机构：
[1] Tampa Gen Hosp, Dept Pharm, Tampa, FL 33606 USA
[2] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA
[3] Univ S Florida, Div Infect Dis & Int Med, Dept Internal Med, Tampa, FL 33620 USA
[4] Univ S Florida, Pulm Crit Care, Tampa, FL 33620 USA
来源：
BMJ CASE REPORTS | 2021年 / 14卷 / 11期
关键词：
infections; malignant disease and immunosuppression; INFECTIONS;
D O I：
10.1136/bcr-2021-243694
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ruxolitinib (RUX) is a kinase inhibitor used in the treatment of various medical conditions and its mechanism of action involves suppression of the immune system. While beneficial in treatment of polycythemia vera, myelofibrosis and other indications, it can also increase a patient's susceptibility to various infections, including bacterial, viral and fungal. We present a case of a patient being treated with RUX who presented with a disseminated fungal infection. This case emphasises the need for vigilance of endemic fungal infections in individuals who are on RUX therapy.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Disseminated tuberculosis mimicking pleural mesothelioma in a polycythemia vera patient treated with ruxolitinib
    Gorospe, L.
    Lario-Arribas, A.
    Lopez-Hernandez, C.
    Caminoa-Lizarralde-Aiza, A.
    Fortun-Abete, J.
    Ajuria-Illarramendi, O.
    PULMONOLOGY, 2024, 30 (06): : 668 - 670
  • [2] THERAPY OF THE POLYCYTHEMIA VERA WITH RUXOLITINIB
    Melikyan, A. L.
    Subortseva, I. N.
    Gilyazitdinova, E. A.
    Kovrigina, A. M.
    Sudarikov, A. B.
    Abdullaev, A. O.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (04): : 229 - 232
  • [3] Ruxolitinib for treatment of polycythemia vera
    Cherington, Chad C.
    Gowin, Krisstina L.
    Mesa, Ruben A.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (09): : 1085 - 1096
  • [4] Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
    Blum, Sabine
    Martins, Filipe
    Alberio, Lorenzo
    JOURNAL OF BLOOD MEDICINE, 2016, 7 : 205 - 215
  • [5] Ruxolitinib for the treatment of patients with polycythemia vera
    Kiladjian, Jean-Jacques
    Winton, Elliott F.
    Talpaz, Moshe
    Verstovsek, Srdan
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (04) : 391 - 401
  • [6] The advantages and risks of ruxolitinib for the treatment of polycythemia vera
    Colafigli, Gioia
    Scalzulli, Emilia
    Pepe, Sara
    Di Prima, Alessio
    Efficace, Fabio
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (10) : 1067 - 1072
  • [7] A safety evaluation of ruxolitinib for the treatment of polycythemia vera
    Boldrini, Valentina
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 1 - 7
  • [8] Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera
    Kremyanskaya, Marina
    Mascarenhas, John
    Hoffman, Ronald
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (08) : 1185 - 1194
  • [9] Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance
    Venugopal, Sangeetha
    Mascarenhas, John
    LANCET HAEMATOLOGY, 2022, 9 (07): : E462 - E463
  • [10] Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?
    Beauverd, Yan
    McLornan, Donal P.
    Radia, Deepti H.
    Harrison, Claire N.
    FUTURE ONCOLOGY, 2016, 12 (06) : 739 - 749
12345